Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose ‐Adjusted EPOCH plus Rituximab

Conclusions The rate of CNS relapse in this patient population approaches 6%, not significantly different from reports on those receiving R‐CHOP. The results of this study suggest that CNS prophylaxis might be more selectively used among patients treated with EPOCH‐R with certain high‐risk features. This article is protected by copyright. All rights reserved.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fajh.24864

Source: American Journal of Hematology - July 18, 2017 Category: Hematology Authors: M.K. Malecek, A.M. Petrich, S. Rozell, B. Chu, S. Trifilio, N. Galanina, M. Maurer, U. Farooq, B. Link, G.S. Nowakowski, C. Nabhan, A.O. Ayed Tags: Research Article Source Type: research